Previous researchers have modelled the decision to accept a donor organ for transplantation as a Markov decision problem, the solution to which is often a control-limit optimal policy: accept any organ whose match quality exceeds some health-dependent threshold; otherwise, wait for another. When competing transplant centers vie for the same organs, the decision rule changes relative to no competition; the relative size of competing centers affects the decision rules as well. Using center-specific graft and patient survival-rate data for cadaveric adult livers in the United States, we have found empirical evidence supporting these predictions
Allocation of liver grafts triggers emotional debates, as those patients, not receiving an organ, ar...
We analyzed the first 100 patients who underwent liver transplantation by Model for End-Stage Liver ...
Liver transplantation is a proven, life-saving therapy for patients with end stage liver disease. 1 ...
In the United States, livers for transplantation are distributed within donation service areas (DSAs...
Transplantation is the only viable therapy for end-stage liverdiseases (ESLD) such as hepatitis B. I...
The only therapy for a patient with end-stage liver disease (ESLD) is liver transplantation, which i...
Since February 2002, the United Network for Organ Sharing (UNOS) proposed to adopt a modified versio...
Survival rates after liver transplantation are currently around 85%, 69% and 61% at 1, 5 and 10 year...
Adoption of the Model for End-stage Liver Disease (MELD) to select and prioritize patients for liver...
As the number of pre- and post-transplant solid organ recipients continues to grow, it becomes impor...
The widespread recognition of the success of liver transplantation as a treatment for most types of ...
Abstract The model for End-stage Liver Disease (MELD) has been adopted by the Organ Procurement and...
In 2009, almost 1,500 Americans died of end-stage liver disease (ESLD), which is the twelfth leading...
none3Adoption of the Model for End-stage Liver Disease (MELD) to select and prioritize patients for ...
In the United States, end-stage liver disease (ESLD) patients are prioritized primarily by their Mod...
Allocation of liver grafts triggers emotional debates, as those patients, not receiving an organ, ar...
We analyzed the first 100 patients who underwent liver transplantation by Model for End-Stage Liver ...
Liver transplantation is a proven, life-saving therapy for patients with end stage liver disease. 1 ...
In the United States, livers for transplantation are distributed within donation service areas (DSAs...
Transplantation is the only viable therapy for end-stage liverdiseases (ESLD) such as hepatitis B. I...
The only therapy for a patient with end-stage liver disease (ESLD) is liver transplantation, which i...
Since February 2002, the United Network for Organ Sharing (UNOS) proposed to adopt a modified versio...
Survival rates after liver transplantation are currently around 85%, 69% and 61% at 1, 5 and 10 year...
Adoption of the Model for End-stage Liver Disease (MELD) to select and prioritize patients for liver...
As the number of pre- and post-transplant solid organ recipients continues to grow, it becomes impor...
The widespread recognition of the success of liver transplantation as a treatment for most types of ...
Abstract The model for End-stage Liver Disease (MELD) has been adopted by the Organ Procurement and...
In 2009, almost 1,500 Americans died of end-stage liver disease (ESLD), which is the twelfth leading...
none3Adoption of the Model for End-stage Liver Disease (MELD) to select and prioritize patients for ...
In the United States, end-stage liver disease (ESLD) patients are prioritized primarily by their Mod...
Allocation of liver grafts triggers emotional debates, as those patients, not receiving an organ, ar...
We analyzed the first 100 patients who underwent liver transplantation by Model for End-Stage Liver ...
Liver transplantation is a proven, life-saving therapy for patients with end stage liver disease. 1 ...